FY2025 · ended Dec 31, 2025 · Revenue $4.14M, -8.5% YoY · Filed Apr 1, 2026
China Pharma Holdings, Inc. (CPHI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.1 million and a net loss of $3.2 million. Free cash flow was $88,937. As of Jun 30, 2026 it held $304,874 in cash and investments and $1.8 million in total debt.
Revenue (TTM)
$3.91M
-11.0% vs year-ago TTM
Net income (TTM)
$-4.47M
-22.4% vs year-ago TTM
Operating cash flow (TTM)
$-140,490
-131.1% vs year-ago TTM
Free cash flow
$88,937
+120.0% vs prior year
EPS
$-0.74
+72.7% vs prior year
Dividend per share
None
Shares outstanding
40.52M
+24.2% vs prior year
Net cash
$-1.49M
as of Jun 30, 2026
Operating margin
-111.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CPHI (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hainan Province, China
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1106644
- Former names
- TS ELECTRONICS INC (until May 4, 2006); SOFTSTONE INC (until Aug 18, 2003); SOFTSTONE INC /DE/ (until Jan 27, 2003); KILKENNY ACQUISITION CORP (until Mar 30, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M |
| Operating income | -$3.2M | -$4.6M | -$2.8M | -$3.5M | -$2.9M |
| Net income | -$3.2M | -$4.7M | -$3.1M | -$4.0M | -$3.4M |
| Diluted EPS | -$0.74 | -$2.71 | -$0.91 | -$3.78 | — |
| Operating cash flow | $148,261 | -$406,063 | -$699,686 | -$409,545 | -$249,838 |
| Free cash flow | $88,937 | -$444,474 | — | -$811,509 | -$687,893 |
| Total assets | $31.0M | $14.9M | $16.5M | $17.8M | $22.6M |
| Total liabilities | $8.3M | $7.1M | $9.0M | $13.5M | $16.6M |
| Stockholders' equity | $22.7M | $7.7M | $7.5M | $4.3M | $6.0M |
| Cash and investments | $345,112 | $626,879 | $1.4M | $2.0M | $4.9M |
| Total debt | $1.6M | $1.2M | $117,637 | $40,445 | $85,282 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 22, 2026 | Jul 22, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 1, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 3, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Feb 10, 2026 | Feb 5, 2026 |
All 426 China Pharma Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.